$GANX News

Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

3 US Biotechs Developing Parkinson’s Therapies

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

Gain Therapeutics To Give Oral Presentation Update On GCase Modulator For Parkinson's Disease At 3rd International GBAI Meeting May 22-23

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Gain Therapeutics Q4 EPS $(0.11) Beats $(0.17) Estimate.

Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference

Gain Therapeutics to Present at the 38th Annual ROTH Conference

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Gain Therapeutics Presents Poster At AD/PD 2026 International Conference on Alzheimer's And Parkinson's Disease And Related Neurological Disorders On New Clinical, Biomarket Data From Phase 1B Clinical Trial Of GT-02287

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Gain Therapeutics Reports Early Parkinson's Trial Results, Drug Cuts Disease Marker by 81% in Early Gain Therapeutics Study

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target